Investing in Autolus Therapeutics PLC Sponsored ADR (AUTL)  ➔  Intrinsic value

Prev. close$6.70 
ModelValueUpside
Chepakovich$2.49-63%
Graham-Dodd$0.00-100%
Graham$0.00-100%
Previous Close$6.70  
Valuation MethodValuePotential 
Chepakovich Model$2.49-63%recalculate
Graham-Dodd$0.00-100%recalculate
Graham Formula$0.00-100%recalculate

Latest news

Company description

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of hematological malignancies and solid tumors. The company is developing AUTO1 and AUTO3 for B cell malignancies; AUTO2 for the treatment of multiple myeloma; AUTO4 and AUTO 5 for T cell lymphoma; and AUTO6 and AUTO7 to treat solid tumors. The company was founded in 2014 and is headquartered in London, the United Kingdom.